research FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects
In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.
Search
forResearch
5 / 1000+ resultsresearch 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.
research Synthesis and Pharmacological Evaluation of New 16-Methyl Pregnane Derivatives.
This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.
research Novel inhibitors of 5α-reductase
This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.
Community Join
1 / 1000+ results
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Learn
— no results
Experts
— no results
Clinics
— no results